HYPERCOAGULABILITY AND THROMBOTIC RISK IN BETA-THALASSEMIA: CLINICAL AND LABORATORY INSIGHTS

Read full text Summarise with VIRAT
Authors: Snezhana Stoencheva
Cited by: 0
References: 28

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Beta-thalassemia is increasingly recognized as a multisystem disorder associated with a chronic hypercoagulable state and an elevated risk of thrombotic complications. Beyond ineffective erythropoiesis, chronic anemia, and transfusion-related iron overload, abnormalities in coagulation and vascular function play an important role in long-term morbidity. Accumulating evidence indicates that patients with beta-thalassemia exhibit persistent activation of cellular and plasma components of hemostasis, even in the absence of overt clinical thrombosis. Hypercoagulability in beta-thalassemia is multifactorial, arising from altered red blood cell membrane architecture with phosphatidylserine externalization, chronic platelet activation, endothelial dysfunction driven by hemolysis and nitric oxide depletion, increased circulating procoagulant microparticles and extracellular vesicles, and imbalances in natural anticoagulant pathways. Iron-related oxidative stress and inflammation further amplify vascular activation and thrombin generation. The magnitude and clinical expression of these abnormalities differ substantially across disease phenotypes. Beta-thalassemia trait is generally not associated with clinically significant thrombosis, whereas non-transfusion-dependent thalassemia (NTDT) carries a particularly high thrombotic burden, especially in splenectomized patients. In transfusion-dependent thalassemia (TDT), regular transfusion modifies erythroid-driven procoagulant mechanisms but introduces additional risk modifiers, including iron overload and catheter-related thrombosis. This review summarizes current knowledge on coagulation disturbances and thrombotic complications in beta-thalassemia, integrating pathophysiological mechanisms with clinically relevant laboratory markers. Particular emphasis is placed on global coagulation assays, cellular biomarkers, and phenotype-specific clinical-laboratory patterns, as well as on contemporary monitoring strategies in TDT. A better understanding of these mechanisms is essential for individualized risk stratification and optimization of thrombosis prevention in patients with beta-thalassemia.

Fields of Study & Subjects

Hemoglobinopathies and Related Disorders Blood Coagulation and Thrombosis Mechanisms Blood properties and coagulation

Publication details

Journal / source
MEDIS – International Journal of Medical Sciences and Research
Volume
5
Issue
1
Pages
33–38
Publication date
21 March 2026
Language
EN